|
GPR183 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.30939999999303E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.220180E-04 |
| Normal-vs-Stage2 |
3.56489999997489E-06 |
| Normal-vs-Stage3 |
5.92539999999531E-05 |
| Normal-vs-Stage4 |
6.49879999999881E-05 |
| Stage1-vs-Stage2 |
4.304200E-03 |
| Stage1-vs-Stage3 |
3.488800E-01 |
| Stage1-vs-Stage4 |
4.463800E-01 |
| Stage2-vs-Stage3 |
7.374000E-02 |
| Stage2-vs-Stage4 |
6.416300E-02 |
| Stage3-vs-Stage4 |
9.430800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.240850E-04 |
| Normal-vs-AfricanAmerican |
1.044550E-03 |
| Normal-vs-Asian |
1.73160999999977E-05 |
| Caucasian-vs-AfricanAmerican |
6.126000E-01 |
| Caucasian-vs-Asian |
9.256800E-03 |
| AfricanAmerican-vs-Asian |
1.146380E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.38149999999271E-05 |
| Normal-vs-Female |
9.98269999999968E-05 |
| Male-vs-Female |
9.221900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.404200E-04 |
| Normal-vs-Age(41-60Yrs) |
2.00719999999821E-05 |
| Normal-vs-Age(61-80Yrs) |
5.72999999999269E-05 |
| Normal-vs-Age(81-100Yrs) |
2.273600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.084500E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.508370E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.259400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.045800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.524800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.284200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.716000E-01 |
| Classical-VS-Follicular |
3.518400E-03 |
| Classical-VS-Other |
7.869200E-01 |
| Classical-VS-Normal |
1.209500E-04 |
| Tall-VS-Follicular |
5.796300E-02 |
| Tall-VS-Other |
8.643000E-01 |
| Tall-VS-Normal |
3.181500E-04 |
| Follicular-VS-Other |
4.068800E-01 |
| Follicular-VS-Normal |
1.58770999999502E-05 |
| Other-VS-Normal |
1.293620E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.03469999999761E-05 |
| Normal-vs-N1 |
9.86669999999412E-05 |
| N0-vs-N1 |
2.417600E-01 |
|
|
